Literature DB >> 28318323

Sublingual, transdermal and intravenous patient-controlled analgesia for acute post-operative pain: systematic literature review and mixed treatment comparison.

Pablo Katz1, Shweta Takyar2, Pamela Palmer3, Hiltrud Liedgens1.   

Abstract

OBJECTIVE: To conduct a systematic literature review (SLR) and quantitative analysis to assess the comparative efficacy and safety of the sufentanil sublingual tablet system (SSTS) against other available patient controlled analgesia (PCA) options for post-operative analgesia.
METHODS: An SLR was conducted for studies published between 2004 and 2016. Due to study heterogeneity, subgroup analyses were conducted controlling for differences in imputation methods for missing values, baseline pain severity, and type of surgery. Where sufficient data was available, a mixed treatment comparison (MTC) was performed.
RESULTS: The MTC and subgroup analyses used 13 studies. In direct meta-analysis, there was a statistically significant difference in favor of SSTS compared with intravenous (IV) PCA (morphine) at 24 hours for the patient global assessment (PGA) scores of "good" or "excellent". For the Pain Intensity Score, there were numerical but not statistically significant differences in favor of the SSTS versus IV PCA (morphine) and the patient controlled transdermal system (PCTS) (fentanyl) in the MTC at 6 hours (standardized mean difference -0.27 [credible interval -2.78, 2.09] and -0.36 [-3.89, 3.03], respectively). The onset of pain relief was earlier with the SSTS versus IV PCA (morphine) as shown by the Pain Intensity Difference. Likewise, the onset was earlier compared with PCTS (fentanyl) where data was available. There was a significant difference in favor of SSTS compared with IV PCA (morphine) and with PCTS (fentanyl) for any adverse event, and numerical improvements for withdrawals due to adverse events.
CONCLUSIONS: This meta-analysis shows that SSTS is an option for non-invasive management of moderate-to-severe post-operative pain which can be more effective, faster in onset and better tolerated than IV PCA (morphine) and PCTS (fentanyl).

Entities:  

Keywords:  Administration; analgesia; analgesics; cutaneous; meta-analysis; opioid; pain; patient-controlled; post-operative; sufentanil; systematic literature review

Mesh:

Substances:

Year:  2017        PMID: 28318323     DOI: 10.1080/03007995.2017.1294559

Source DB:  PubMed          Journal:  Curr Med Res Opin        ISSN: 0300-7995            Impact factor:   2.580


  6 in total

1.  Feasibility and effectiveness of multi-injection thoracic paravertebral block via the intrathoracic approach for analgesia after thoracoscopic-laparoscopic esophagectomy.

Authors:  Lihong Hu; Xia Xu; Weiyu Shen; Jinxian He
Journal:  Esophagus       Date:  2021-01-06       Impact factor: 4.230

Review 2.  A Review of Sublingual Sufentanil Tablet (SST) and its Utility as an Analgesic Agent for Pain Procedures.

Authors:  Sarang S Koushik; Ruben H Schwartz; Denis Cherkalin; Vignesh Sankar; Naum Shaparin; Omar Viswanath
Journal:  Curr Pain Headache Rep       Date:  2022-01-25

3.  Between evidence and commerce - the case of sufentanil sublingual tablet systems.

Authors:  C Bantel; H C Laycock
Journal:  Anaesthesia       Date:  2017-12-08       Impact factor: 6.955

4.  Sublingual sufentanil for postoperative pain relief: first clinical experiences.

Authors:  Fleur Meijer; Petra Cornelissen; Corina Sie; Michel Wagemans; Anja Mars; Tiny Hobma; Marieke Niesters; Albert Dahan; J Seppe Koopman; Monique Ah Steegers
Journal:  J Pain Res       Date:  2018-05-24       Impact factor: 3.133

Review 5.  The rising crisis of illicit fentanyl use, overdose, and potential therapeutic strategies.

Authors:  Ying Han; Wei Yan; Yongbo Zheng; Muhammad Zahid Khan; Kai Yuan; Lin Lu
Journal:  Transl Psychiatry       Date:  2019-11-11       Impact factor: 6.222

6.  Efficacy and Safety of Continuous Paravertebral Block after Minimally Invasive Radical Esophagectomy for Esophageal Cancer.

Authors:  Shifa Zhang; Hongfeng Liu; Haibo Cai
Journal:  Pain Res Manag       Date:  2020-04-21       Impact factor: 3.037

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.